Michael Wolf

28.8k total citations · 10 hit papers
188 papers, 19.9k citations indexed

About

Michael Wolf is a scholar working on Statistics and Probability, Oncology and Finance. According to data from OpenAlex, Michael Wolf has authored 188 papers receiving a total of 19.9k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Statistics and Probability, 43 papers in Oncology and 38 papers in Finance. Recurrent topics in Michael Wolf's work include Statistical Methods and Inference (31 papers), Financial Risk and Volatility Modeling (30 papers) and Statistical Methods in Clinical Trials (28 papers). Michael Wolf is often cited by papers focused on Statistical Methods and Inference (31 papers), Financial Risk and Volatility Modeling (30 papers) and Statistical Methods in Clinical Trials (28 papers). Michael Wolf collaborates with scholars based in United States, Switzerland and Germany. Michael Wolf's co-authors include Olivier Ledoit, Joseph P. Romano, Salvatore Siena, Marc Peeters, Eric Van Cutsem, Rafael G. Amado, Roy S. Herbst, Steven D. Averbuch, Ronald B. Natale and Joan H. Schiller and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Journal of the American Statistical Association.

In The Last Decade

Michael Wolf

182 papers receiving 19.1k citations

Hit Papers

Wild-Type KRAS Is Required for Panitumumab Efficacy in Pa... 1999 2026 2008 2017 2008 2003 2003 2007 2004 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
    2008 2.4k citations Rafael G. Amado, Michael Wolf et al. Journal of Clinical Oncology profile →
  2. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
    2003 2.1k citations Ronald B. Natale, Michael Wolf et al. profile →
  3. A well-conditioned estimator for large-dimensional covariance matrices
    2003 1.7k citations Olivier Ledoit, Michael Wolf Journal of Multivariate Analysis profile →
  4. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
    2007 1.5k citations Eric Van Cutsem, Marc Peeters et al. Journal of Clinical Oncology profile →
  5. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
    2004 1.4k citations Ronald B. Natale, Michael Wolf et al. Journal of Clinical Oncology profile →
  6. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
    2004 1.4k citations Ronald B. Natale, Michael Wolf et al. Journal of Clinical Oncology profile →
  7. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
    2010 1.4k citations Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology profile →
  8. Improved estimation of the covariance matrix of stock returns with an application to portfolio selection
    2003 1.0k citations Olivier Ledoit, Michael Wolf profile →
  9. Robust performance hypothesis testing with the Sharpe ratio
    2008 623 citations Olivier Ledoit, Michael Wolf profile →
  10. Subsampling
    1999 513 citations Michael Wolf et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Wolf United States 50 9.6k 6.8k 3.4k 2.8k 2.6k 188 19.9k
Peter A. Hall United Kingdom 84 5.7k 0.6× 1.8k 0.3× 4.3k 1.2× 3.9k 1.4× 7.2k 2.7× 350 38.2k
Donald A. Berry United States 78 14.6k 1.5× 4.0k 0.6× 170 0.0× 2.4k 0.8× 4.5k 1.7× 375 31.9k
Jeremy M. G. Taylor United States 72 4.0k 0.4× 4.2k 0.6× 181 0.1× 919 0.3× 5.1k 1.9× 402 22.0k
John D. Kalbfleisch United States 51 1.6k 0.2× 1.5k 0.2× 608 0.2× 2.6k 0.9× 917 0.3× 143 24.1k
Jun S. Liu United States 83 4.0k 0.4× 3.7k 0.6× 393 0.1× 498 0.2× 24.1k 9.1× 483 44.0k
Mike West United States 52 1.4k 0.2× 562 0.1× 1.1k 0.3× 1.5k 0.5× 4.9k 1.9× 147 14.9k
Dongsheng Tu Canada 64 15.6k 1.6× 8.6k 1.3× 137 0.0× 736 0.3× 4.3k 1.6× 313 25.5k
Wing Hung Wong United States 74 1.4k 0.1× 948 0.1× 537 0.2× 917 0.3× 14.2k 5.4× 262 26.7k
David Peel United Kingdom 57 829 0.1× 712 0.1× 2.3k 0.7× 4.7k 1.7× 1.9k 0.7× 469 15.8k
Hemant Ishwaran United States 47 2.2k 0.2× 2.1k 0.3× 174 0.1× 319 0.1× 2.5k 1.0× 107 11.5k

Countries citing papers authored by Michael Wolf

Since Specialization
Citations

This map shows the geographic impact of Michael Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Wolf more than expected).

Fields of papers citing papers by Michael Wolf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Wolf. The network helps show where Michael Wolf may publish in the future.

Co-authorship network of co-authors of Michael Wolf

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Wolf. A scholar is included among the top collaborators of Michael Wolf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Wolf. Michael Wolf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rebay‐Salisbury, Katharina, et al.. (2025). More Error than Minority: Gendered Burial Practices Align with Peptide-based Sex Identification in Early Bronze Age Burials in Central Europe. Cambridge Archaeological Journal. 35(3). 456–471. 3 indexed citations
2.
Ledoit, Olivier, et al.. (2024). Improved Tracking-Error Management for Active and Passive Investing. The Journal of Portfolio Management. 51(4). 40–62.
3.
Nguyen, Phuong Anh & Michael Wolf. (2023). Single-firm inference in event studies via the permutation test. Empirical Economics. 66(6). 2435–2450.
4.
Serra, Teresa, Margarida Serra, Ana Carina Silva, et al.. (2019). Scalable Culture Strategies for the Expansion of Patient-Derived Cancer Stem Cell Lines. Stem Cells International. 2019. 1–7. 5 indexed citations
5.
Miesbach, Wolfgang, Jan Menne, Martin Bommer, et al.. (2019). Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study. Orphanet Journal of Rare Diseases. 14(1). 260–260. 27 indexed citations
6.
7.
Wolf, Michael. (2013). Subsampling tests of parameter hypotheses and overidentifying restrictions with possible failure of identification. International Journal of Approximate Reasoning. 54(6). 769–792. 1 indexed citations
8.
Wurz, Gregory T., et al.. (2012). L-BLP25 Vaccine plus Letrozole Induces a TH1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice. Clinical Cancer Research. 18(10). 2861–2871. 16 indexed citations
9.
DeGregorio, Michael W., et al.. (2012). L-BLP25 vaccine plus letrozole for breast cancer. OncoImmunology. 1(8). 1422–1424. 10 indexed citations
10.
Douillard, Jean‐Yves, Salvatore Siena, James T. Cassidy, et al.. (2010). Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. Journal of Clinical Oncology. 28(31). 4697–4705. 1351 indexed citations breakdown →
11.
Siena, Salvatore, Jean‐Yves Douillard, James T. Cassidy, et al.. (2010). Prime study : a randomised phase 3 study of panitumumab with Folfox4 versus Folfox4 alone as first line treatment for metastatic colorectal cancer (mCRC). Annals of Oncology. 21. 1 indexed citations
12.
Amado, Rafael G., Michael Wolf, Marc Peeters, et al.. (2008). Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 26(10). 1626–1634. 2400 indexed citations breakdown →
13.
Siena, Salvatore, Marc Peeters, Eric Van Cutsem, et al.. (2007). Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. British Journal of Cancer. 97(11). 1469–1474. 65 indexed citations
14.
Wolf, Michael, Henrik Edgren, Ian G. Mills, et al.. (2006). Integrated DNA/RNA microarray profiling of hormone-refractory clinical prostate cancers and metastases indicates deregulation of several pathways, including androgen/AR, Hedgehog, MAPK and neuroactive ligand/receptor signalling. Cancer Research. 66. 1 indexed citations
15.
Ledoit, Olivier & Michael Wolf. (2003). A well-conditioned estimator for large-dimensional covariance matrices. Journal of Multivariate Analysis. 88(2). 365–411. 1726 indexed citations breakdown →
16.
Wolf, Michael. (2000). Stock Returns and Dividend Yields Revisited: A New Way to Look at an Old Problem. Journal of Business and Economic Statistics. 18(1). 18–30. 55 indexed citations
17.
18.
Williamson, Stephen K., Michael Wolf, Mario A. Eisenberger, et al.. (1996). Phase II Evaluation of Ifosfamide/Mesna in Metastatic Prostate Cancer. American Journal of Clinical Oncology. 19(4). 368–370. 6 indexed citations
19.
Marshall, M. Ernest, Michael Wolf, E. David Crawford, et al.. (1995). Phase II Trial of CHIP for the Treatment of Advanced, Hormonally Refractory Carcinoma of the Prostate. American Journal of Clinical Oncology. 18(5). 400–402. 4 indexed citations
20.
Allen, Ace, et al.. (1992). Phase II evaluation of piroxantrone in renal cell carcinoma. Investigational New Drugs. 10(2). 129–132. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter A. Hall Breakdown of academic impact, for papers by Donald A. Berry Breakdown of academic impact, for papers by Jeremy M. G. Taylor Breakdown of academic impact, for papers by John D. Kalbfleisch Breakdown of academic impact, for papers by Jun S. Liu Breakdown of academic impact, for papers by Mike West Breakdown of academic impact, for papers by Dongsheng Tu Breakdown of academic impact, for papers by Wing Hung Wong Breakdown of academic impact, for papers by David Peel Breakdown of academic impact, for papers by Hemant Ishwaran
Rankless by CCL
2026